细胞因子诱导杀伤细胞治疗晚期肺癌的临床疗效观察

目的:探讨细胞因子诱导杀伤（cytokine induced killer，CIK）细胞在晚期肺癌中的治疗价值。方法:收集遵义医学院附属医院腹部肿瘤科2011年1 月至2013年12月经病理诊断的晚期肺癌患者90例，分为观察组41例和对照组49例，观察组进行最佳支持治疗的同时给予CIK 治疗；对照组仅给予最佳支持治疗，并在入组前1 个月内未行放化疗。对两组患者进行生存随访，比较两组生存质量（KPS 评分）和生存期，并观察不良反应。结果:观察组治疗后KPS 评分较对照组提高，差异具有统计学意义（P =0.034）；观察组的中位生存期为8 个月，高于对照组的7 个月，中位生存期差为1 个月（P = 0.044）；主要不良反应为发热（51.22%）、关节酸痛（36.58%）和失眠（29.27%）。结论:CIK 细胞治疗晚期肺癌患者可提高生存质量和延长生存期，不良反应可耐受。 

Efficacy of cytokine-induced killer cells on patients with advanced lung cancer

Objective:To observe the efficacy of cytokine-induced killer (CIK) cells on patients with advanced lung cancer. Methods:A total of 90 patients with advanced lung cancer were identified from January 2011 to December 2013. CIK therapy was given to 41 pa-tients in the observation group, whereas the other 49 patients in the control group received the best support treatments without che-motherapy or radiotherapy within one month of inclusion. Following up was conducted for the patients in the two groups, and KPS scores, median survival, and adverse reactions compared. Results:The KPS score in the observation group was higher than that of the control group after treatment (P=0.034). The median survival period of the observation group was eight months, which was one month longer than that of the control group (P=0.044). Major adverse reactions included fever, joint pain, and insomnia, which were recorded 51.22%, 36.58%, and 29.27%of occurrence, respectively. Conclusion:CIK cell therapy improved the quality of life and pro-longed the survival of advanced lung cancer patients with tolerable adverse reactions.